Cap

Zacks Small Cap Research – SDOT: Sadot Group Reports 2024 Financial Results Which Showed the First Full Year Positive Net Income in the Company’s History – Go Health Pro

by

By Thomas Kerr, CFA NASDAQ:SDOT READ THE FULL SDOT RESEARCH REPORT 4th Quarter and Full Year 2024 Financial Results On March 11, 2025, Sadot Group (NASDAQ:SDOT) reported 4th quarter and full year 2024 results which showed continued strength in the commodity trading business. In the latest filings, the restaurant operations have been reported as discontinued … Read more

Zacks Small Cap Research – MGRM: Monogram Technologies Reports 4th Quarter and Full Year 2024 Results – Go Health Pro

by
Zacks Small Cap Research – MGRM: Monogram Technologies Reports 4th Quarter and Full Year 2024 Results – Go Health Pro

By Thomas Kerr, CFA NASDAQ:MGRM READ THE FULL MGRM RESEARCH REPORT 4th Quarter and Full Year 2024 Financial Results Monogram (NASDAQ:MGRM) reported 4th quarter and full year 2024 financial results on March 12th which were largely in line with our expectations. Research and development expenses for 2024 were $8.8 million compared to $10.6 million in … Read more

Zacks Small Cap Research – RERE: 4Q24 Earnings Review: EPS as Expected; Investing for Growth to Keep Pace with Accelerating Demand – Go Health Pro

by

By Michael Kim NYSE:RERE READ THE FULL RERE RESEARCH REPORT Pre-market open on 3/11/25, ATRenew (NYSE:RERE) reported 4Q24 earnings results. On a GAAP basis, RERE reported net income of $10.6 million for 4Q24, or $0.04 per ADS. That said, excluding non-cash share-based compensation and intangible assets amortization expenses, adjusted EPS came in at $0.07, or … Read more

Zacks Small Cap Research – REVB Starts 2025 With Bright Future Ahead – Go Health Pro

by

By Brad Sorensen, CFA NASDAQ:REVB READ THE FULL REVB RESEARCH REPORT Revelation Biosciences (NASDAQ:REVB) is a life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease. Revelation has multiple product candidates in development that we believe have promising potential and are based on the biology of phosphorylated hexaacyl … Read more

Zacks Small Cap Research – CVKD: Collaborating with Abbott for Pivotal Phase 3 Trial… – Go Health Pro

by

By David Bautz, PhD NASDAQ:CVKD READ THE FULL CVKD RESEARCH REPORT Business Update Collaboration Agreement with Abbott for Phase 3 TECH-LVAD Trial On March 4, 2025, Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) announced a collaboration agreement with Abbott for the Phase 3 TECarfarin Anticoagulation and Hemocompatibility with Left Ventricular Assist Devices (TECH-LVAD) trial. In August 2024, Cadrenal … Read more

x